Clinical trial
Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder
NCT03494738 is registered in ClinicalTrials.gov with CAMC Health System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder
- Lead sponsor
- CAMC Health System
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 12, 2018
- Completion date
- December 31, 2022
- Enrollment
- 600 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.